Marjolein van Egmond received her Ph.D. from University Medical Center Utrecht, The Netherlands. In 2000 she transferred to the VU Medical Center, Amsterdam, The Netherlands, where she started her own research group ?Inflammation and Cancer?.
Van Egmond is currently Associate Professor, and responsible for the supervision of several Ph.D students and Post-Docs working on the relationship between (surgery-induced) inflammation and tumor development. In addition, the potential of targeting tumors with antibody therapy has become a major research topic.
Due to Van Egmond’s affiliations with a research department (Molecular Cell Biology and Immunology) and a clinical department (Surgery), she is in an excellent position to translate experimental findings into clinical applications, which recently resulted in initiation of several clinical trials.
To support her research Van Egmond received multiple grants including a VENI (2003), VIDI (2007) and VICI (2014) of the prestigious Innovational Research Incentives Scheme (Netherlands Organization for Scientific Research / NWO). In 2009 she was nominated for the Amsterdam Inventors Award.
Content from this contributor:
- Macrophages are ?big eaters? indeed: Circulating tumor cells are devoured after monoclonal antibody therapy.[Article]
Photo: Marjolein van Egmond, Ph.D. Photo Courtesy: DigiDaan
Copyright ? 2014 InPress Media Group/Sunvalley Communication. All rights reserved. Republication or redistribution of InPress Media Group/Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group/Sunvalley Communication. InPress Media Group/Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.